close

Agreements

1 2 3 209
Number of results: 4164

Excel print is not allowed for data more than 3000.Please search above for fewer data.

Date Company Compound Disease Type of agreement Therapeutic area Type of Information
2017-06-26 University of Cambridge (UK) Genomics England Ltd (UK) Illumina (USA) 100,000 Genomes Project rare genetic diseases, cancers collaboration Genetic diseases - Rare diseases - Cancer - Oncology Collaboration agreement
2017-06-26 Takeda Pharmaceutical (Japan) Biological E. (India) measles vaccines and acellular pertussis vaccine measles, pertussis licensing Infectious diseases Licensing agreement
2017-06-19 Txcell (France) Lentigen Technology (USA - MD), a wholly owned subsidiary of Miltenyi Biotech (Germany) HLA?A2 CAR lentiviral vector prevention of chronic rejection after organ transplantation services contract manufacturing bioproduction Transplantation Services contract
2017-06-15 CitoxLab (France) KaLy-Cell (France) in vitro and ex vivo testing for hepatotoxicity and metabolism collaboration Technology - Services Collaboration agreement
2017-06-12 Zealand Pharma (Denmark) Helsinn Healthcare (Switzerland) elsiglutide chemotherapy-induced diarrhea termination of an agreement Cancer - Oncology Termination of an agreement
2017-06-12 Tiziana Life Sciences (UK) nomination Autoimmune diseases - Cancer - Oncology Nomination
2017-06-09 Ascensia Diabetes Care (Switzerland) Voluntis (France) insulin management solutions. type 2 diabetes development Metabolic diseases Development agreement
2017-06-08 Vertex Pharmaceuticals (USA - MA) nomination Rare diseases - Genetic diseases Nomination
2017-06-05 CTI BioPharma - previously known as Cell Therapeutics (USA - WA) nomination Cancer - Oncology Nomination
2017-06-05 Novartis (Switzerland) IBM Watson Health (USA - NY) cognitive solution to provide insights on the expected outcomes of breast cancer treatment options breast cancer collaboration Cancer - Oncology Collaboration agreement
2017-06-02 BMS (USA - NY) Seattle Genetics (USA - WA) Adcetris® (brentuximab vedotin) and Opdivo® (nivolumab) relapsed or refractory Hodgkin lymphoma, relapsed or refractory B-cell and T-cell non-Hodgkin lymphomas (NHL), including diffuse large B-cell lymphoma (DLBCL) clinical research Cancer - Oncology Clinical research agreement
2017-06-02 Innate Pharma (France) Novo Nordisk (Denmark) anti-C5aR (IPH5401) product acquisition Cancer - Oncology Product acquisition
2017-05-31 AstraZeneca (UK) nomination Nomination
2017-05-31 Array BioPharma (USA - CO) Ono Pharmaceutical (Japan) binimetinib and encorafenib licensing, development, commercialisation Licensing agreement
2017-05-31 Baxalta (USA - IL) Mayo Clinic (USA - MN) research - R&D Kidney diseases - Renal diseases Research agreement
2017-05-30 Array BioPharma (USA - CO) BMS (USA - NY) binimetinib in combination with Opdivo® (nivolumab) and Opdivo® + Yervoy® (ipilimumab) metastatic colorectal cancer in patients with microsatellite stable tumors clinical research Cancer - Oncology Clinical research agreement
2017-05-23 Nabriva Therapeutics (Austria) Nabriva Ireland (Ireland) establishment of a new subsidiary in the EU Infectious diseases Establishment of a new subsidiary in the EU
2017-05-16 Noxxon Pharma (Germany) National Center for Tumor Diseases (NCT) in Heidelberg (Germany) NOX-A12 (olaptesed pegol) and Keytruda® (pembrolizumab) metastatic pancreatic cancer, metastatic colorectal cancer clinical research Cancer - Oncology Clinical research agreement
2017-05-16 Oryzon Genomics (Spain) nomination Nomination
2017-05-15 Akebia Therapeutics (USA - MA) Vifor Pharma (Switzerland) Fresenius Medical Care (Germany) vadadustat anemia associated with chronic kidney disease licensing Kidney diseases - Renal diseases Licensing agreement